Shares of AstraZeneca rose on Friday after the drugmaker reported positive results from late-stage clinical trials of its ...

GD analyst, Vinie Varkey notes that tozorakimab could capture a "significant patient share" as an add-on therapy in COPD.

AstraZeneca stock jumped Friday after the U.K.-based drugmaker said its COPD drug succeeded in two final-phase studies.

Tozorakimab is an investigational monoclonal antibody designed to bind and inhibit interleukin-33, an alarmin cytokine.

AstraZeneca's IL-33-targeting antibody tozorakimab has made the grade in two phase 3 chronic obstructive pulmonary disease ...

AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) shares rose 3% to 14,230p, placing the drugmaker at the top of the FTSE 100 leaderboard ...

The treatment, tozorakimab, succeeded where other similar therapies failed and could help a broader group of COPD patients ...

Escalating to extrafine single-inhaler triple therapy significantly reduces exacerbations in patients with moderate to severe COPD.

Russell Winwood's chronic obstructive pulmonary disease (COPD) diagnosis in 2011 was a brutal wake-up call. His second in less than a decade. The Brisbane native, who came to be known as the “COPD ...

You did it to yourself.” This is one of the things that patients who are diagnosed with COPD often hear because of the stigma ...